We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+0.51%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$522M
AUM Growth
-$124M
Cap. Flow
-$115M
Cap. Flow %
-22.13%
Top 10 Hldgs %
61.71%
Holding
72
New
27
Increased
15
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$12.5M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$11.2M
3
VTRS icon
Viatris
VTRS
+$9.9M
4
ARQL
Arqule Inc
ARQL
+$9.88M
5
TXMD icon
TherapeuticsMD
TXMD
+$8.01M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$19.3M
2
PCRX icon
Pacira BioSciences
PCRX
+$18.2M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$16.5M
4
CLLS
Cellectis
CLLS
+$15.5M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$15.2M

Sector Composition

Rank Sector Weight
1 Healthcare 65.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
26
PUT
Eli Lilly
LLY
$1.08T
$5.37M 1.03%
+50,000
New +$5M
PFE icon
27
PUT
Pfizer
PFE
$143B
$5.29M 1.01%
+126,480
New +$4.87M
INSM icon
28
PUT
Insmed
INSM
$22.4B
$5.05M 0.97%
+250,000
New +$5.65M
FOMX
29
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.28M 0.82%
+747,308
New +$4.28M
ZSAN
30
DELISTED
Zosano Pharma Corporation
ZSAN
$4.23M 0.81%
29,536
+9,536
+48% +$1.4M
STRO icon
31
Sutro Biopharma
STRO
$386M
$3.47M 0.67%
+23,161
New +$3.5M
IOVA icon
32
Iovance Biotherapeutics
IOVA
$2.04B
$3.34M 0.64%
+296,500
New +$4.21M
KYNB
33
Kyntra Bio
KYNB
$27.4M
$3.06M 0.59%
2,017
-3,406
-63% -$5.25M
HRTX icon
34
Heron Therapeutics
HRTX
$93.4M
$2.84M 0.55%
+89,849
New +$3.35M
CARM
35
DELISTED
Carisma Therapeutics
CARM
$2.53M 0.49%
+58,850
New +$2.29M
TGTX icon
36
TG Therapeutics
TGTX
$8.19B
$2.49M 0.48%
445,000
+372,800
+516% +$4.26M
CHMA
37
DELISTED
Chiasma, Inc. Common Stock
CHMA
$2.29M 0.44%
+636,646
New +$1.33M
ONCS
38
DELISTED
OncoSec Medical Incorporated
ONCS
$1.94M 0.37%
6,313
-5,570
-47% -$1.71M
DNTH icon
39
Dianthus Therapeutics
DNTH
$5.69B
$1.8M 0.35%
9,375
– –
NEOS
40
DELISTED
Neos Therapeutics, Inc
NEOS
$1.51M 0.29%
311,502
-67,459
-18% -$383K
OMED
41
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$1.35M 0.26%
+634,715
New +$1.52M
SGYP
42
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1.27M 0.24%
+746,200
New +$1.34M
DCPH
43
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.19M 0.23%
30,622
-99,178
-76% -$3.66M
CLSD
44
DELISTED
Clearside Biomedical
CLSD
$1.11M 0.21%
+12,067
New +$1.43M
SVRA icon
45
Savara
SVRA
$1.08B
$1.09M 0.21%
+97,600
New +$1.12M
MDWD icon
46
MediWound
MDWD
$184M
$1.06M 0.2%
24,725
+18,357
+288% +$824K
PRQR icon
47
ProQR Therapeutics
PRQR
$244M
$1.02M 0.2%
+52,875
New +$562K
ADAP
48
DELISTED
Adaptimmune Therapeutics
ADAP
$1M 0.19%
+74,132
New +$777K
ACOR
49
DELISTED
Acorda Therapeutics
ACOR
$983K 0.19%
417
-820
-66% -$2.54M
ACAD icon
50
Acadia Pharmaceuticals
ACAD
$4.51B
$913K 0.18%
+43,980
New +$692K
1
2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Nexthera Capital held 72 positions worth $522M, down 19% from $646M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Nexthera Capital withdrew a net $115M in Q3 2018, closing 16 positions and reducing 12 holdings. Its most notable exit was TESARO, Inc., an estimated $19.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 60% a quarter earlier.

Against the trend, Nexthera Capital opened a new position in Bausch Health worth $14M.

  • Nexthera Capital's largest Q3 2018 buy was Bausch Health: 545,500 shares worth $14M.
  • Nexthera Capital added most to Audentes Therapeutics, Inc in Q3 2018, an estimated $11.2M increase.
  • Nexthera Capital's biggest Q3 2018 reduction was AstraZeneca, cutting an estimated $12.4M.
  • Nexthera Capital fully exited TESARO, Inc. in Q3 2018, selling an estimated $19.3M.
  • Nexthera Capital's ten largest holdings make up 62% of its $522M portfolio in Q3 2018.
  • Nexthera Capital opened 27 new positions and closed 16 in Q3 2018.
  • Nexthera Capital's portfolio value fell 19% quarter-over-quarter to $522M.

Based on Nexthera Capital's 13F filing for Q3 2018, filed 14 Nov 2018.